Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Cash from Operations (2019 - 2025)

Historic Cash from Operations for BioScience Health Innovations (BHIC) over the last 7 years, with Q3 2025 value amounting to -$340445.0.

  • BioScience Health Innovations' Cash from Operations fell 75178.14% to -$340445.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $222569.0, marking a year-over-year increase of 120646.28%. This contributed to the annual value of $23188.0 for FY2024, which is 10753.24% up from last year.
  • As of Q3 2025, BioScience Health Innovations' Cash from Operations stood at -$340445.0, which was down 75178.14% from $285010.0 recorded in Q2 2025.
  • BioScience Health Innovations' 5-year Cash from Operations high stood at $328309.0 for Q1 2025, and its period low was -$340445.0 during Q3 2025.
  • Moreover, its 5-year median value for Cash from Operations was -$25027.0 (2022), whereas its average is -$5851.7.
  • Per our database at Business Quant, BioScience Health Innovations' Cash from Operations plummeted by 92093.43% in 2021 and then soared by 78340.76% in 2025.
  • Quarter analysis of 5 years shows BioScience Health Innovations' Cash from Operations stood at -$5901.0 in 2021, then plummeted by 372.97% to -$27910.0 in 2022, then tumbled by 102.28% to -$56457.0 in 2023, then grew by 10.9% to -$50305.0 in 2024, then plummeted by 576.76% to -$340445.0 in 2025.
  • Its Cash from Operations was -$340445.0 in Q3 2025, compared to $285010.0 in Q2 2025 and $328309.0 in Q1 2025.